All In Biotech

NDA 020963 · Sandoz

Timolol Maleate

Timolol Maleate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: May 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Oct 21, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

306

98 Phase 3, 14 recruiting

FAERS reports

7,784

3,677 serious, 439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 28, 2024.

Timolol GFS 0.25% and 0.5% are indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Timolol GFS is a beta adrenergic blocker indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma ( 1 ).

Mechanism: Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Timolol GFS, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. The precise mechanism of the ocular hypotensive action of Timolol GFS is not...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TIMOLOL MALEATE · TIMOLOL MALEATE EQ 0.25% BASE · SOLUTION, GEL FORMING/DROPS, OPHTHALMIC · Prescription · TE AB
  • TIMOLOL MALEATE · TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION, GEL FORMING/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure983
  • drug ineffective579
  • eye pain441
  • fatigue410
  • eye irritation362
  • dizziness291
  • diarrhoea284
  • vision blurred268
  • nausea260
  • off label use260
  • headache245
  • ocular hyperaemia233

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004158
2005193
2006156
2007142
2008136
2009133
2010202
2011219
2012309
2013108
2014132
2015252
2016294
2017364
2018367
2019399
20201,435
2021409
2022438
2023514
2024516
2025558
2026349

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Timolol Maleate (Timolol Maleate/PF)

2024 spending

$9.3M

Beneficiaries

9,480

28,017 claims

Per beneficiary

$977

$3.64 per unit

View as table
YearSpending
2020$171,392
2021$5,930,854
2022$8,101,964
2023$9,682,202
2024$9,261,267

Part D: Timolol Maleate* (Timolol Maleate)

2024 spending

$51.3M

Beneficiaries

837,015

2,958,063 claims

Per beneficiary

$61

$2.01 per unit

View as table
YearSpending
2020$73,879,256
2021$71,093,138
2022$68,190,043
2023$63,904,505
2024$51,254,561

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,308 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.